TWD 361.5
(-0.14%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 6.78 Billion TWD | 7.41% |
2022 | 6.32 Billion TWD | 12.98% |
2021 | 5.59 Billion TWD | 40.64% |
2020 | 3.97 Billion TWD | 18.58% |
2019 | 3.35 Billion TWD | 7.1% |
2018 | 3.13 Billion TWD | 43.56% |
2017 | 2.18 Billion TWD | 31.51% |
2016 | 1.65 Billion TWD | 26.9% |
2015 | 1.3 Billion TWD | 41.99% |
2014 | 920.93 Million TWD | 56.27% |
2013 | 589.31 Million TWD | 156.52% |
2012 | 229.73 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 1.72 Billion TWD | -15.34% |
2024 Q2 | 1.63 Billion TWD | -5.03% |
2024 Q3 | 1.65 Billion TWD | 1.26% |
2023 Q1 | 1.45 Billion TWD | -17.83% |
2023 Q3 | 1.67 Billion TWD | 3.83% |
2023 Q2 | 1.61 Billion TWD | 10.66% |
2023 Q4 | 2.03 Billion TWD | 21.5% |
2023 FY | 6.78 Billion TWD | 7.41% |
2022 Q4 | 1.77 Billion TWD | 8.19% |
2022 Q2 | 1.41 Billion TWD | -4.95% |
2022 FY | 6.32 Billion TWD | 12.98% |
2022 Q1 | 1.48 Billion TWD | -4.25% |
2022 Q3 | 1.64 Billion TWD | 16.05% |
2021 Q1 | 1.14 Billion TWD | -18.92% |
2021 FY | 5.59 Billion TWD | 40.64% |
2021 Q4 | 1.55 Billion TWD | 2.71% |
2021 Q3 | 1.51 Billion TWD | 9.56% |
2021 Q2 | 1.38 Billion TWD | 20.56% |
2020 Q2 | 835.38 Million TWD | 15.79% |
2020 FY | 3.97 Billion TWD | 18.58% |
2020 Q3 | 1 Billion TWD | 20.7% |
2020 Q1 | 721.44 Million TWD | -27.76% |
2020 Q4 | 1.41 Billion TWD | 40.16% |
2019 Q3 | 856.21 Million TWD | 15.61% |
2019 Q2 | 740.58 Million TWD | -2.51% |
2019 Q1 | 759.61 Million TWD | -10.64% |
2019 FY | 3.35 Billion TWD | 7.1% |
2019 Q4 | 998.71 Million TWD | 16.64% |
2018 Q4 | 850.07 Million TWD | -1.95% |
2018 FY | 3.13 Billion TWD | 43.56% |
2018 Q3 | 867 Million TWD | 13.34% |
2018 Q2 | 764.92 Million TWD | 8.07% |
2018 Q1 | 707.79 Million TWD | 19.15% |
2017 Q3 | 594.05 Million TWD | 19.52% |
2017 Q1 | 497.03 Million TWD | 12.48% |
2017 FY | 2.18 Billion TWD | 31.51% |
2017 Q4 | 594.05 Million TWD | 0.0% |
2017 Q2 | 497.03 Million TWD | 0.0% |
2016 Q1 | 387.76 Million TWD | 8.94% |
2016 Q2 | 387.76 Million TWD | 0.0% |
2016 Q3 | 441.9 Million TWD | 13.96% |
2016 FY | 1.65 Billion TWD | 26.9% |
2016 Q4 | 441.9 Million TWD | 0.0% |
2015 Q4 | 355.94 Million TWD | 0.0% |
2015 Q2 | 297.86 Million TWD | 0.0% |
2015 Q3 | 355.94 Million TWD | 19.5% |
2015 Q1 | 297.86 Million TWD | 6.45% |
2015 FY | 1.3 Billion TWD | 41.99% |
2014 Q2 | 180.66 Million TWD | 0.0% |
2014 Q3 | 279.8 Million TWD | 54.88% |
2014 FY | 920.93 Million TWD | 56.27% |
2014 Q4 | 279.8 Million TWD | 0.0% |
2014 Q1 | 180.66 Million TWD | 15.67% |
2013 Q2 | 138.47 Million TWD | 0.0% |
2013 Q4 | 156.18 Million TWD | 0.0% |
2013 Q1 | 138.47 Million TWD | 0.0% |
2013 FY | 589.31 Million TWD | 156.52% |
2013 Q3 | 156.18 Million TWD | 12.79% |
2012 FY | 229.73 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 2.15 Billion TWD | -215.774% |
Maxigen Biotech Inc. | 622.11 Million TWD | -991.416% |
SciVision Biotech Inc. | 712.98 Million TWD | -852.311% |
Bionime Corporation | 1.75 Billion TWD | -286.762% |
Visco Vision Inc. | 2.39 Billion TWD | -183.185% |